Charles River Laboratories Gross Profit 2010-2025 | CRL

Charles River Laboratories annual/quarterly gross profit history and growth rate from 2010 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Charles River Laboratories gross profit for the quarter ending March 31, 2025 was $0.318B, a 7.86% decline year-over-year.
  • Charles River Laboratories gross profit for the twelve months ending March 31, 2025 was $1.305B, a 11.23% decline year-over-year.
  • Charles River Laboratories annual gross profit for 2024 was $1.332B, a 11.36% decline from 2023.
  • Charles River Laboratories annual gross profit for 2023 was $1.503B, a 2.73% increase from 2022.
  • Charles River Laboratories annual gross profit for 2022 was $1.463B, a 9.59% increase from 2021.
Charles River Laboratories Annual Gross Profit
(Millions of US $)
2024 $1,332
2023 $1,503
2022 $1,463
2021 $1,335
2020 $1,074
2019 $958
2018 $840
2017 $701
2016 $644
2015 $531
2014 $473
2013 $395
2012 $392
2011 $402
2010 $385
2009 $423
Charles River Laboratories Quarterly Gross Profit
(Millions of US $)
2025-03-31 $318
2024-12-31 $284
2024-09-30 $349
2024-06-30 $354
2024-03-31 $345
2023-12-31 $364
2023-09-30 $362
2023-06-30 $399
2023-03-31 $378
2022-12-31 $399
2022-09-30 $370
2022-06-30 $357
2022-03-31 $337
2021-12-31 $347
2021-09-30 $337
2021-06-30 $342
2021-03-31 $308
2020-12-31 $300
2020-09-30 $289
2020-06-30 $232
2020-03-31 $252
2019-12-31 $262
2019-09-30 $246
2019-06-30 $238
2019-03-31 $212
2018-12-31 $226
2018-09-30 $216
2018-06-30 $216
2018-03-31 $181
2017-12-31 $167
2017-09-30 $177
2017-06-30 $185
2017-03-31 $171
2016-12-31 $177
2016-09-30 $156
2016-06-30 $170
2016-03-31 $141
2015-12-31 $141
2015-09-30 $138
2015-06-30 $133
2015-03-31 $120
2014-12-31 $120
2014-09-30 $118
2014-06-30 $126
2014-03-31 $109
2013-12-31 $88
2013-09-30 $100
2013-06-30 $103
2013-03-31 $104
2012-12-31 $91
2012-09-30 $93
2012-06-30 $104
2012-03-31 $104
2011-12-31 $101
2011-09-30 $93
2011-06-30 $106
2011-03-31 $103
2010-12-31 $94
2010-09-30 $91
2010-06-30 $101
2010-03-31 $99
2009-12-31 $94
2009-09-30 $107
2009-06-30 $114
2009-03-31 $108
Sector Industry Market Cap Revenue
Medical Medical Services $7.829B $4.050B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $146.605B 27.50
CVS Health (CVS) United States $81.948B 10.19
Elevance Health (ELV) United States $76.969B 9.93
Cencora (COR) United States $57.218B 19.91
DiDi Global (DIDIY) China $24.191B 25.70
Natera (NTRA) United States $21.906B 0.00
Labcorp Holdings (LH) United States $20.893B 16.95
BioMerieux (BMXMF) France $16.861B 0.00
EUROFINS SCIENT (ERFSF) Luxembourg $13.687B 0.00
CochLear (CHEOY) Australia $12.827B 0.00
Solventum (SOLV) United States $12.768B 13.52
ICON (ICLR) Ireland $12.156B 11.30
Revvity (RVTY) United States $11.964B 20.59
Viatris (VTRS) United States $10.704B 3.68
Medpace Holdings (MEDP) United States $9.298B 24.69
Avantor (AVTR) United States $9.254B 13.45
Sonic Healthcare (SKHHY) Australia $8.638B 0.00
HealthEquity (HQY) United States $8.174B 35.80
Caris Life Sciences,�Inc (CAI) United States $6.744B 0.00
Amplifon S.p.A (AMFPF) Italy $5.378B 29.44
Bausch + Lomb (BLCO) Canada $4.911B 28.92
BrightSpring Health Services (BTSG) United States $3.571B 32.76
Sotera Health (SHC) United States $3.349B 19.03
Surgery Partners (SGRY) United States $2.825B 36.73
Alignment Healthcare (ALHC) United States $2.645B 0.00
Organon (OGN) United States $2.584B 2.75
Concentras Parent (CON) United States $2.551B 14.74
GeneDx Holdings (WGS) United States $2.356B 90.73
Ardent Health (ARDT) United States $2.027B 8.64
Progyny (PGNY) United States $1.990B 43.79
PACS (PACS) United States $1.932B 0.00
Premier (PINC) United States $1.736B 13.18
GoodRx Holdings (GDRX) United States $1.695B 33.89
Teladoc Health (TDOC) United States $1.460B 0.00
Establishment Labs Holdings (ESTA) $1.298B 0.00
Pediatrix Medical (MD) United States $1.127B 8.58
CareDx (CDNA) United States $1.121B 17.50
Ryman Healthcare (RYHTY) New Zealand $0.970B 0.00
Agilon Health (AGL) United States $0.923B 0.00
QDM (QDMI) Hong Kong, SAR China $0.848B 291.00
AMN Healthcare Services Inc (AMN) United States $0.810B 7.58
Nutex Health (NUTX) United States $0.637B 9.64
Embecta (EMBC) United States $0.612B 4.12
InnovAge Holding (INNV) United States $0.559B 0.00
SBC Medicals (SBC) United States $0.523B 0.00
LifeMD (LFMD) United States $0.512B 0.00
Sonida Senior Living (SNDA) United States $0.482B 0.00
Auna S.A (AUNA) Luxembourg $0.471B 10.60
Omada Health (OMDA) $0.455B 0.00
So-Young (SY) China $0.390B 0.00
Enhabit (EHAB) United States $0.357B 29.38
COMPASS Pathways (CMPS) United Kingdom $0.344B 0.00
Performant Healthcare (PHLT) United States $0.321B 0.00
Oncology Institute (TOI) United States $0.279B 0.00
Beauty Health (SKIN) United States $0.241B 0.00
DocGo (DCGO) United States $0.152B 24.83
Pheton Holdings (PTHL) China $0.138B 0.00
Sera Prognostics (SERA) United States $0.107B 0.00
Ascend Wellness Holdings (AAWH) United States $0.079B 0.00
KindlyMD (NAKA) United States $0.074B 0.00
IceCure Medical (ICCM) Israel $0.061B 0.00
NeueHealth (NEUE) United States $0.061B 0.00
ModivCare (MODV) United States $0.046B 0.00
Biodesix (BDSX) United States $0.045B 0.00
Basel Medical Group (BMGL) Singapore $0.042B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.035B 0.00
OSR Holdings (OSRH) United States $0.023B 0.00
Intelligent Bio Solutions (INBS) United States $0.012B 0.00
BioNexus Gene Lab (BGLC) $0.009B 0.00
Co-Diagnostics (CODX) United States $0.008B 0.00
SeaStar Medical Holding (ICU) United States $0.007B 0.00
XWELL (XWEL) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
INVO Fertility (IVF) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.000B 0.00